Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies
about
NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potentialHeme-dependent and independent soluble guanylate cyclase activators and vasodilation.Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl ratsStimulation of soluble guanylyl cyclase protects against obesity by recruiting brown adipose tissueStimulation of soluble guanylyl cyclase inhibits mesangial cell proliferation and matrix accumulation in experimental glomerulonephritis.Targeting soluble guanylate cyclase for the treatment of pulmonary hypertension.Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase stimulator, BAY 41-8543, are modulated by nitric oxide.Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase activator, BAY 60-2770, are not dependent on endogenous nitric oxide or reduced heme.New perspectives for the treatment of pulmonary hypertensionSoluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease.Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studiesNO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle.Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.The soluble guanylyl cyclase activator YC-1 increases intracellular cGMP and cAMP via independent mechanisms in INS-1E cellsSoluble guanylyl cyclase: physiological role as an NO receptor and the potential molecular target for therapeutic application.Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation.Pathophysiology of hypertension in the absence of nitric oxide/cyclic GMP signaling.Analysis of erectile responses to BAY 41-8543 and muscarinic receptor stimulation in the ratActivation of endothelial nitric oxide synthase by the pro-apoptotic drug embelin: Striking discrepancy between nitric oxide-mediated cyclic GMP accumulation and L-citrulline formationThe future of the oral pharmacotherapy of male erectile dysfunction: things to come.Inhalative and intravenous stimulation of soluble guanylate cyclase reduces pulmonary vascular resistance and increases cardiac output in experimental septic shock.Novel therapeutic strategies targeting vascular endothelium in essential hypertension.A Review of the Pathophysiology and Novel Treatments for Erectile Dysfunction.Guanylate cyclase activators, cell volume changes and IOP reduction.Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications.Soluble guanylate cyclase: a potential therapeutic target for heart failure.Review of companies and drug classes in the 2007-2011 antihypertensive patent literature.Regulation of sGC via hsp90, Cellular Heme, sGC Agonists, and NO: New Pathways and Clinical Perspectives.Nitric oxide in paediatric respiratory disorders: novel interventions to address associated vascular phenomena?Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation.NO-independent stimulation or activation of soluble guanylyl cyclase during early reperfusion limits infarct size.Analysis of responses to glyceryl trinitrate and sodium nitrite in the intact chest rat.Platelet hyperaggregability in high-fat fed rats: a role for intraplatelet reactive-oxygen species production.The sGC stimulator riociguat inhibits platelet function in washed platelets but not in whole blood.Soluble guanylate cyclase: an old therapeutic target re-visited.Identification of residues crucially involved in the binding of the heme moiety of soluble guanylate cyclase.Novel soluble guanylyl cyclase stimulator BAY 41-2272 attenuates ischemia-reperfusion-induced lung injury.An enzyme-linked receptor mechanism for nitric oxide-activated guanylyl cyclase.The soluble guanylate cyclase stimulator IW-1973 prevents inflammation and fibrosis in experimental non-alcoholic steatohepatitis.Stimulators and activators of soluble guanylate cyclase for urogenital disorders.
P2860
Q24656131-568AD5E6-FBCF-4133-8F52-EC4C602CCC1CQ27692662-1EEFA0CD-B67D-4693-8B61-EE5375C3CAA3Q28742463-2D8B4459-5795-4C45-969E-C0CDEEAEFD5FQ30316523-88056041-BDAB-461C-8C43-9EFD81426925Q33209298-7527E656-0A8A-42C8-9F77-3FCC94B12ABCQ34179857-8A91BC01-36FF-49C3-860E-E4489600E955Q34212268-526B2144-A841-4309-A824-5E8274303183Q34720361-1C72C93A-8E52-4A77-B861-EBFF23DCD0C1Q34903204-9FD2C421-5C44-4CE4-BAB5-FEA54B1DA3D3Q35010064-C92F6667-E863-4ABB-9838-C49514AD34DAQ35044037-35D4DA1E-8B75-408B-AF32-F9CE75FBA583Q35044464-EA1FF709-166D-428C-AB42-271653FD5197Q35075847-864AC001-3D22-4A03-A3E4-B42B977D0A38Q35188169-82650826-4BB6-4C68-BE88-A2810B06DA1CQ35206512-932C30E3-211B-47EF-A743-B58DDC58D35DQ36330594-6FFFD70A-0FAA-4DFF-A033-98F1CB53DB78Q36532454-C80DFF95-49C2-485C-BD44-295BF2E2D4E0Q36674593-BCF2771D-642D-489E-84D8-0251E2C82050Q36838279-79350C74-6F17-4574-A67A-14463C7A9926Q36866594-E1DDEF71-E9B2-4905-9DA3-AA4AEA4843C2Q37734554-2A9D54BD-6CD5-4F3D-B9D8-D7EAAFED26F9Q37798006-C7149A99-802B-4EE2-8DF7-B1FD63FCB834Q37820206-9E35CCD7-9946-47AE-862C-8F21DA2EE267Q37969557-DB4C2E7F-7EA0-470C-8C09-9AFF7535B164Q38000562-226C1044-26B8-4C46-A2CB-ED20D0292B99Q38012596-3F1F2A8E-3027-4FB3-B48F-B1A2BC46AEA6Q38162898-B255E3DE-6F6E-44B1-9332-CBE485D69770Q38777323-710BE9AB-BB78-4587-8674-18674964054AQ38842183-1376CA29-4DD5-4420-9BA2-231EE1E7D96EQ39847509-9344119B-6FF7-4CF3-A30B-B9ABDD59205FQ41879996-2AC749A0-F761-4C2F-B230-4A59B8B40492Q42502151-13958752-35BE-4A5F-A591-6BC44A2786E3Q42555438-F49B7A57-CA5D-43CA-BBBF-1C3B3C640230Q43119916-E043FC50-BC10-4661-9FFC-515CD3E10F5DQ43263737-8ECF22BB-DB28-4D2B-9A05-B7D8D15E4B17Q44626758-83677A37-EC50-4272-B2A1-DEDB1ABC8BF1Q46202369-453A7B9A-14FC-4AF6-871D-72F109942922Q46607492-08DFFBAD-AE62-40DE-8EAC-E9F94736D159Q47243685-9F1E87B5-15F2-4C00-9F78-F51572896501Q47603923-E07E924B-F558-4261-A3A7-1F7A19413227
P2860
Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Pharmacological actions of a n ...... BAY 41-8543: in vitro studies
@en
type
label
Pharmacological actions of a n ...... BAY 41-8543: in vitro studies
@en
prefLabel
Pharmacological actions of a n ...... BAY 41-8543: in vitro studies
@en
P2093
P2860
P356
P1476
Pharmacological actions of a n ...... BAY 41-8543: in vitro studies
@en
P2093
Achim Feurer
Alexander Straub
Cristina Alonso-Alija
Elisabeth Perzborn
Heiner Apeler
Klaus Dembowsky
Matthias Schramm
Torsten Minuth
P2860
P304
P356
10.1038/SJ.BJP.0704484
P407
P577
2002-01-01T00:00:00Z